87 related articles for article (PubMed ID: 27517656)
1. Dose-effect relationship of perindopril 10, 14 and 20mg assessed by urine and plasma AcSDKP levels in mildly sodium-depleted healthy volunteers.
Monge M; Paquet V; Bergerot D; Zhygalina V; Blanchard A
Int J Cardiol; 2016 Nov; 222():648-653. PubMed ID: 27517656
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
Azizi M; Bissery A; Peyrard S; Guyene TT; Ozoux ML; Floch A; Ménard J
Clin Pharmacol Ther; 2006 Jan; 79(1):49-61. PubMed ID: 16413241
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Junot C; Ezan E; Ménard J
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317
[TBL] [Abstract][Full Text] [Related]
4. Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats.
Junot C; Nicolet L; Ezan E; Gonzales MF; Menard J; Azizi M
J Pharmacol Exp Ther; 1999 Dec; 291(3):982-7. PubMed ID: 10565814
[TBL] [Abstract][Full Text] [Related]
5. The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans.
Wuerzner G; Peyrard S; Blanchard A; Lalanne F; Azizi M
J Hypertens; 2009 Jul; 27(7):1404-9. PubMed ID: 19506528
[TBL] [Abstract][Full Text] [Related]
6. Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients.
Kwakernaak AJ; Waanders F; Slagman MC; Dokter MM; Laverman GD; de Boer RA; Navis G
J Hypertens; 2013 Dec; 31(12):2425-32. PubMed ID: 24029871
[TBL] [Abstract][Full Text] [Related]
7. Subjective and Cardiovascular Effects of Intravenous Methamphetamine during Perindopril Maintenance: A Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study.
Verrico CD; Haile CN; De La Garza R; Grasing K; Kosten TR; Newton TF
Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 27207905
[TBL] [Abstract][Full Text] [Related]
8. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans.
Azizi M; Ezan E; Reny JL; Wdzieczak-Bakala J; Gerineau V; Ménard J
Hypertension; 1999 Mar; 33(3):879-86. PubMed ID: 10082503
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor.
Azizi M; Massien C; Michaud A; Corvol P
Hypertension; 2000 Jun; 35(6):1226-31. PubMed ID: 10856268
[TBL] [Abstract][Full Text] [Related]
10. Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study.
Azizi M; Ménard J; Peyrard S; Lièvre M; Marre M; Chatellier G
Diabetes Care; 2006 Jun; 29(6):1331-6. PubMed ID: 16732017
[TBL] [Abstract][Full Text] [Related]
11. Experience with perindopril in normal volunteers.
Waeber B; Nussberger J; Perret L; Santoni JP; Brunner HR
Clin Exp Hypertens A; 1989; 11 Suppl 2():507-19. PubMed ID: 2605800
[TBL] [Abstract][Full Text] [Related]
12. Experience with perindopril in normal volunteers.
Waeber B; Nussberger J; Perret L; Santoni JP; Brunner HR
Arch Mal Coeur Vaiss; 1989 May; 82 Spec No 1():35-41. PubMed ID: 2549899
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers.
Anderson PJ; Critchley JA; Tomlinson B; Resplandy G
Br J Clin Pharmacol; 1995 Apr; 39(4):361-8. PubMed ID: 7640141
[TBL] [Abstract][Full Text] [Related]
14. The effect of perindopril on blood pressure in humans on different sodium intakes.
Morgan T; Anderson A; Wilson D; Murphy J; Nowson C
J Cardiovasc Pharmacol; 1987; 10 Suppl 7():S116-8. PubMed ID: 2485043
[TBL] [Abstract][Full Text] [Related]
15. Effect of perindopril on cerebral vasomotor reactivity in patients with lacunar infarction.
Walters M; Muir S; Shah I; Lees K
Stroke; 2004 Aug; 35(8):1899-902. PubMed ID: 15166388
[TBL] [Abstract][Full Text] [Related]
16. Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers.
Azizi M; Blanchard A; Charbit B; Wuerzner G; Peyrard S; Ezan E; Funck-Brentano C; Ménard J
Hypertension; 2013 Jun; 61(6):1239-45. PubMed ID: 23608658
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of perindopril.
Lees KR
J Hum Hypertens; 1990 Oct; 4 Suppl 4():7-8; discussion 9-11. PubMed ID: 2283658
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
[TBL] [Abstract][Full Text] [Related]
19. [Modeling of the relation between plasma concentration of the active metabolite of perindopril and inhibition of the activity of plasma converting enzyme in healthy volunteers].
Bellissant E; Chau NP; Thuillez C; Giudicelli JF
Arch Mal Coeur Vaiss; 1990 Jul; 83(8):1285-9. PubMed ID: 2175584
[TBL] [Abstract][Full Text] [Related]
20. [Peripheral hemodynamic and biological effects of perindopril in the healthy subject. Dose-effect relationship].
Richer C; Thuillez C; Desmichels D; Giudicelli JF
Arch Mal Coeur Vaiss; 1986 Jun; 79(6):913-8. PubMed ID: 3026273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
